HomeAI · summaries
Storia in 3 fonti
Pfizer's good-enough obesity data in a crowded market may force competition on price, dosing
Pfizer's berobenatide shows up to 10.2% weight loss and 2.2% blood sugar reduction in Phase 2b trial in patients with obesity and type 2 diabetes.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Detailed data show Pfizer’s monthly obesity drug continues to show potential
Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.
- ·
endpoints.news
Pfizer's good-enough obesity data in a crowded market may force competition on price, dosing
Pfizer's berobenatide shows up to 10.2% weight loss and 2.2% blood sugar reduction in Phase 2b trial in patients with obesity and type 2 diabetes.
